

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=623	N
Age	69.0 (11.3)	623
Sex: Men	393 (63.1%)	623
Tumor level:		623
0-6cm	225 (36.1%)	
7-12cm	323 (51.8%)	
13-15cm	75 (12.0%)	
Tumor stage:		623
0	104 (16.7%)	
I	171 (27.4%)	
II	172 (27.6%)	
III	176 (28.3%)	
Neoadjuvant treatment	455 (73.0%)	623
Type of resection:		623
Abdominoperineal resection	173 (27.8%)	
Anterior resection	422 (67.7%)	
Hartmann	28 (4.49%)	
Perforation	23 (3.69%)	623
Invasion circumferential margin	40 (6.42%)	623
Mesorecto quality:		614
Satisfactory	561 (91.4%)	
Partial	42 (6.84%)	
No-satisfactory	11 (1.79%)	
Recidive	17 (2.73%)	623
Months to recidive	28.0 [7.00;59.0]	623
Metastasis	51 (8.19%)	623
Months to Metastasis	27.0 [6.00;58.0]	623
Exitus	86 (13.8%)	623
Months to exitus	30.0 [7.00;60.0]	623


Table 2: According to Local Recurrence

	No event n= 606	Event n= 17	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.91 (1.13)	6.68 (1.13)	0.93 [0.60;1.42]	0.724	0.99 [0.64; 1.51]	0.95	623
Sex: Men	380 (62.7%)	13 (76.5%)	2.05 [0.67;6.28]	0.211	2.07 [0.67; 6.46]	0.208	623
Tumor level:							623
0-6cm	220 (36.3%)	5 (29.4%)	1.08 [0.21;5.56]	0.928	1.51 [0.21;10.58]	0.681	
7-12cm	313 (51.7%)	10 (58.8%)	1.31 [0.29;5.97]	0.730	1.41 [0.29; 6.97]	0.673	
Tumor stage:							623
0	103 (17.0%)	1 (5.88%)	0.42 [0.05;3.77]	0.440	0.46 [0.05; 4.26]	0.493	
II	167 (27.6%)	5 (29.4%)	1.53 [0.41;5.71]	0.524	1.41 [0.37; 5.43]	0.617	
III	169 (27.9%)	7 (41.2%)	2.08 [0.61;7.09]	0.244	1.69 [0.47; 6.15]	0.424	
Neoadjuvant treatment	442 (72.9%)	13 (76.5%)	1.03 [0.34;3.16]	0.961	1.23 [0.36; 4.14]	0.739	623
Type of resection:							623
Abdominoperineal resection	170 (28.1%)	3 (17.6%)	0.84 [0.24;2.96]	0.782	0.64 [0.13; 3.20]	0.588	
Hartmann	26 (4.29%)	2 (11.8%)	3.16 [0.71;14.1]	0.132	2.24 [0.47;10.64]	0.31	
Perforation	22 (3.63%)	1 (5.88%)	2.49 [0.33;18.8]	0.375	1.82 [0.20;16.23]	0.592	623
Invasion circumferential margin	37 (6.11%)	3 (17.6%)	3.88 [1.11;13.5]	0.033	3.57 [0.91;13.89]	0.067	623
Mesorecto quality:							614
Partial	41 (6.87%)	1 (5.88%)	1.02 [0.13;7.66]	0.988	1.08 [0.14; 8.51]	0.94	
No-satisfactory	11 (1.84%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.998	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	623	431	337	269	202	154


Table 3: According to Metastasis

	No event n= 572	Event n= 51	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.93 (1.12)	6.62 (1.26)	0.86 [0.68;1.09]	0.212	0.91 [0.71;1.16]	0.441	623
Sex: Men	357 (62.4%)	36 (70.6%)	1.48 [0.81;2.70]	0.203	1.46 [0.79;2.68]	0.227	623
Tumor level:							623
0-6cm	206 (36.0%)	19 (37.3%)	1.28 [0.51;3.19]	0.604	1.66 [0.58;4.77]	0.349	
7-12cm	297 (51.9%)	26 (51.0%)	1.10 [0.45;2.66]	0.840	1.19 [0.47;3.00]	0.713	
Tumor stage:							623
0	103 (18.0%)	1 (1.96%)	0.14 [0.02;1.11]	0.063	0.13 [0.02;1.00]	0.05	
II	161 (28.1%)	11 (21.6%)	1.13 [0.49;2.61]	0.773	1.08 [0.46;2.54]	0.864	
III	148 (25.9%)	28 (54.9%)	2.95 [1.47;5.93]	0.002	2.73 [1.33;5.59]	0.006	
Neoadjuvant treatment	415 (72.6%)	40 (78.4%)	1.19 [0.61;2.32]	0.606	1.32 [0.65;2.68]	0.444	623
Type of resection:							623
Abdominoperineal resection	161 (28.1%)	12 (23.5%)	1.03 [0.53;1.97]	0.938	0.80 [0.35;1.81]	0.595	
Hartmann	25 (4.37%)	3 (5.88%)	1.51 [0.46;4.89]	0.496	1.02 [0.31;3.37]	0.976	
Perforation	21 (3.67%)	2 (3.92%)	1.57 [0.38;6.46]	0.532	1.10 [0.24;5.10]	0.903	623
Invasion circumferential margin	33 (5.77%)	7 (13.7%)	3.00 [1.35;6.67]	0.007	2.21 [0.95;5.14]	0.066	623
Mesorecto quality:							614
Partial	39 (6.93%)	3 (5.88%)	0.98 [0.30;3.13]	0.966	0.93 [0.28;3.08]	0.909	
No-satisfactory	10 (1.78%)	1 (1.96%)	1.00 [0.14;7.25]	1.000	0.97 [0.12;7.67]	0.978	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	623	423	327	258	193	146

Table 4: According to Exitus


	No event n= 537	Event n= 86	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.81 (1.12)	7.50 (1.05)	1.97 [1.57;2.47]	<0.001	1.90 [1.50;2.41]	<0.001	623
Sex: Men	334 (62.2%)	59 (68.6%)	1.34 [0.85;2.11]	0.212	1.39 [0.87;2.20]	0.164	623
Tumor level:							623
0-6cm	197 (36.7%)	28 (32.6%)	1.57 [0.68;3.59]	0.289	2.13 [0.82;5.53]	0.121	
7-12cm	272 (50.7%)	51 (59.3%)	1.84 [0.83;4.05]	0.130	2.05 [0.89;4.70]	0.091	
Tumor stage:							623
0	98 (18.2%)	6 (6.98%)	0.45 [0.18;1.10]	0.081	0.63 [0.25;1.59]	0.324	
II	144 (26.8%)	28 (32.6%)	1.44 [0.82;2.52]	0.201	1.43 [0.80;2.53]	0.226	
III	146 (27.2%)	30 (34.9%)	1.50 [0.87;2.61]	0.146	1.54 [0.87;2.73]	0.137	
Neoadjuvant treatment	402 (74.9%)	53 (61.6%)	0.53 [0.35;0.82]	0.005	0.62 [0.39;1.00]	0.049	623
Type of resection:							623
Abdominoperineal resection	148 (27.6%)	25 (29.1%)	1.38 [0.86;2.22]	0.182	1.14 [0.62;2.07]	0.679	
Hartmann	21 (3.91%)	7 (8.14%)	2.32 [1.05;5.10]	0.037	1.43 [0.62;3.28]	0.405	
Perforation	20 (3.72%)	3 (3.49%)	1.19 [0.38;3.78]	0.765	0.78 [0.23;2.64]	0.683	623
Invasion circumferential margin	31 (5.77%)	9 (10.5%)	2.03 [1.01;4.04]	0.045	1.63 [0.76;3.49]	0.208	623
Mesorecto quality:							614
Partial	34 (6.42%)	8 (9.52%)	1.62 [0.78;3.35]	0.197	1.28 [0.60;2.71]	0.52	
No-satisfactory	9 (1.70%)	2 (2.38%)	1.32 [0.32;5.37]	0.700	0.95 [0.22;4.02]	0.943	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	623	432	344	278	205	157

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	173	108	75	61	47	34
Ant	422	317	259	207	163	116
H	28	17	14	10	5	4

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	173	108	76	60	42	29
Ant	422	308	249	197	156	113
H	28	17	14	10	5	4

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	173	108	77	62	48	34
Ant	422	317	263	215	165	119
H	28	18	15	11	5	4

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	0.42 [0.99; 0]	3.77 [5.43; 2.08]	7.24 [9.34; 5.09]
24	2.27 [3.73; 0.79]	7.51 [9.94; 5.02]	10.31 [12.9; 7.64]
36	3.81 [5.77; 1.82]	10.31 [13.25; 7.27]	14.3 [17.48; 11]
48	4.59 [6.8; 2.33]	12.62 [16; 9.11]	18.11 [21.82; 14.22]
60	5.19 [7.67; 2.65]	13.67 [17.29; 9.89]	20.83 [24.98; 16.46]